Context server on a mobile device

Da bi mobilne aplikacije lahko učinkovito nudile vse svoje storitev in jih prilagodile uporabniku, bi morale pri tem uporabiti ves kontekst uporabnika in njegove okolice. V obstoječih raziskavah to nalogo prevzema poseben kontekstni strežnik, ki skrbi za zbiranje podatkov ter posredovanje informacij aplikaciji. V primeru, da bi tak kontekstni strežnik deloval na mobilni napravi, bi bila postopoma odpravljena potreba po omenjenem sistemu. V sklopu naloge smo predlagani model kontekstnega strežnika uspešno implementirali in njegovo delovanje preizkusili s pomočjo kontekstno odvisne aplikacije, ki deluje na principu tekstovne klasifikacije uporabnikovih vnosov v spletnih iskalnikih in njegovi trenutni lokaciji. Aplikaciji omenjenih podatkov ni potrebno zajeti ročno, saj so ti ob pojavitvi novega podatka avtomatično posredovani preko kontekstnega strežnika.In order for mobile applications to efficiently offer all of their services and adjust them according to the end user, they would need to monitor all of his context and surroundings. In the existing researches this is done by a special context server which is responsible for data retrieval and transmission of information application. In the event, when the context server would work on a mobile device, the before mentioned system would gradually not be needed anymore. In the context of the thesis we have successfully implemented the proposed model of context server and tested it with a context application, which operates in the principle of text classification of user entries in the search engines and its current location. The application of this data does not need to be captured manually, since they are automatically transmitted to the server when the new data appears

Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study

Background Limited options are available for treatment of paediatric psoriasis. Objectives To evaluate the efficacy and safety of ustekinumab in paediatric patients with psoriasis (>= 6 to = 60 to 100 kg: 90 mg) administered by subcutaneous injection at weeks 0 and 4, then every 12 weeks through week 40. Study endpoints (all at week 12) included the proportions of patients achieving a Physician's Global Assessment score of cleared/minimal (PGA 0/1) and >= 75%/90% improvement in Psoriasis Area and Severity Index (PASI 75/90), and change in Children's Dermatology Life Quality Index (CDLQI). Serum ustekinumab concentrations, antidrug antibodies and cytokine levels were measured through week 52. Safety was evaluated through week 56. Results In total, 44 patients (median age 9 center dot 5 years) received at least one dose of ustekinumab. Three patients discontinued the study agent through week 40. At week 12, 77% of patients achieved PGA 0/1, 84% achieved PASI 75 and 64% achieved PASI 90 response. The mean change in CDLQI was -6 center dot 3. Trough serum ustekinumab concentrations reached steady state at weeks 28-52. The incidence of antidrug antibodies was 10% (n = 4). Mean serum concentrations of interleukin-17A/F and interleukin-22 were significantly reduced at weeks 12 and 52. Overall, 34 patients (77%) had at least one adverse event and three (7%) had a serious adverse event. Conclusions Ustekinumab effectively treated moderate-to-severe psoriasis in paediatric patients, and no new safety concerns were identified. What is already known about this topic? Ustekinumab is approved for use in adolescents (>= 12 to = 18 years) with moderate-to-severe psoriasis. What does this study add? Ustekinumab effectively treats moderate-to-severe psoriasis in paediatric patients (>= 6 to < 12 years of age), with no new safety concerns

Supplementary Material for: Risk Factors for Skin Infections in Mycosis Fungoides

<p><b><i>Background:</i></b> Mycosis fungoides (MF) is the most frequent type of primary cutaneous natural killer and T-cell lymphoma. MF-required immunosuppressive therapies and MF-related immunosuppressive characteristics render patients with MF more prone to infections. <b><i>Aim:</i></b> To describe the clinical features of cutaneous infections observed in MF patients. <b><i>Materials and Methods:</i></b> A series of 56 MF patients were followed prospectively over 3 years and screened for cutaneous infections. <b><i>Type of Study:</i></b> Prospective observational study. <b><i>Results:</i></b> Four herpes simplex virus type-I (HSV-I), 2 staphylococcal (<i>S. aureus</i>) impetiginizations and 2 <i>Malassezia</i> infections were detected in single isolated plaque/patch stage MF as well as 1 varicella zoster virus infection (herpes zoster, HZ) and 2 cases of cellulitis in 10 patients. All patients presented advanced MF. All the diagnoses were delayed due to atypical clinical presentations. <b><i>Conclusions:</i></b> Patients with advanced MF should be particularly monitored for skin infections, especially by HSV and <i>S. aureus</i>. Unexplained exacerbation or the sudden appearance of oozing or ulcerations in MF lesions should initiate a search for viral or bacterial agents. Cellulitis and HZ can be severer and prolonged in MF patients.</p

The clinical relevance of off-label photodynamic therapy in onco-dermatology

BACKGROUND :Besides actinic keratosis, Bowen's disease, as well as superficial and small nodular basal cell carcinoma, aminolevulinic acid and methylaminolevulinic acid photodynamic therapy (ALA-PDT, MAL-PDT) present a broad potential of experimental indications in oncologic skin conditions. AIM :To present the various off-label indications with their respective PDT protocols, treatment results, level of evidence (A, B, C, D levels), and potential clinical interest. MATERIAL AND METHODS :A Pubmed search matched PDT with actinic cheilitis, anal, vulvar, and penile intraepithelial neoplasia (AIN, VIN, PIN), verrucous carcinoma, Paget disease, extramammary Paget disease, cutaneous B-cell lymphoma (CBCL), cutaneous T-cell lymphoma (CTCL), and cutaneous metastases of breast carcinoma. RESULTS :All indications presented interesting complete and partial cures, even in cases faling on previous standard treatments. All publications score C and D levels of evidence. The best PDT outcomes and the lowest recurrence rates concerned unifocal oncologic skin conditions with limited extension. Direct comparison of treatment data was difficult, as PDT protocols were highly variable. Comparative therapeutic trials vs standard care were rarely available. CONCLUSION :PDT represents a valuable treatment alternative in selected off-label oncologic skin conditions. However, literature data are too limited to support a hierarchic treatment position for PDT or a preferential protocol in these specific indications. There is a clear need for clinical trials evaluationg PDT vs standard treatments. In contrast to the approved PDT indications, where clinical evaluation accurately matches histologica evaluation, histology is required in these off- label indications to ensure treatment efficacy. Off-label use of PDT should be measured against the advantages and inconveniencies of standar treatment procedures.info:eu-repo/semantics/publishe

Schöpf-Schulz-Passarge syndrome with pili torti: A new association?

SCOPUS: le.jinfo:eu-repo/semantics/publishe

Dermatological complications of temporary and indelible tattoos

info:eu-repo/semantics/publishe

Le crémage a du plomb dans l'aile.

Topical treatment is the cornerstone of therapy for patients suffering from psoriasis. Its efficacy and safety have been demonstrated in a large number of publications. However, in daily life, the treatment outcome is often less satisfactory than the results published in the literature. This phenomenon is clearly linked to non-adherence. Indeed, patients with psoriasis frequently consider the topical therapies frequently as a heavy burden. The successful management of psoriasis with topical agents requires a perfect understanding between the patient and the practionner, which provides regular renewal of the patient's motivation.English AbstractJournal Articleinfo:eu-repo/semantics/publishe